Mean BMI was markedly higher in GLP-1 users (36.55±5.19 kg/m2 vs. 28.61±6.71 kg/m2; p<0.001), consistent with the medication's indication for obesity and type 2 diabetes management. This evidence concerns the gene GLP1R and obesity disorder.